A randomized, placebo-controlled, three-way crossover study to evaluate the effect of SCH 497079 on metabolic parameters and to determine the influence of race/ethnic origin on therapeutic response.

Trial Profile

A randomized, placebo-controlled, three-way crossover study to evaluate the effect of SCH 497079 on metabolic parameters and to determine the influence of race/ethnic origin on therapeutic response.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Metformin; SCH 497079
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 17 Dec 2008 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 17 Dec 2008 Status changed from recruiting to completed.
    • 25 Sep 2008 Planned end date changed from 1 Dec 2008 to 1 Dec 2009 as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top